ITM RP-München GmbH – Radiopharmazie München™  - is responsible for the development of the portfolio and pipeline of radiopharmaceutical products in oncology/personalized medicine.

RPMs main focus are the so called Targeted or Peptide Receptor Radioisotope Therapies, which have already proven their medical effectiveness and commercial viability in the treatment of various metastatic tumours.

Providing Isotopes for the PRRT of NETs has become the fastest growing business for itg over the past two years and it is now RPMs responsibility to also strategically secure the market position at the top of the PRRT value chain for the itm group. In this context an innovative peptide with a multistage targeting and internalization mechanism has been licensed and has been brought into pre-clinical development by RPM. First promising results in a wide variety of vascularized tumours and metastatic melanoma could be obtained.

For further information please contact:

• This e-mail address is being protected from spambots. You need JavaScript enabled to view it

RP-München GmbH

Lichtenbergstrasse 1
85748 Garching
Germany
Phone: +49 89 289-13940
Fax: +49 89 32707676